Claims:

1. Use of peanut protein in the manufacture of a medicament for the treatment of peanut allergy in an individual, wherein the medicament is to be administered as follows:

(1) wherein the medicament is to be orally administered daily, wherein the daily oral dose is increased at intervals of at least 2 weeks in a series of increments from an initial dose to a maximum dose, the series of dose increments including 2mg, 5mg, 12.5mg, 25mg, 50mg, 100mg, 200mg, 400mg and 800mg,

(2) wherein a daily oral dose of the maximum dose of peanut protein is to be administered for at least 2 years following step 1,

(3) wherein a weekly oral dose of the maximum dose of peanut protein is to be administered for at least 2 years following step 2.

2. A use according to claim 1 wherein the initial dose is 2mg.

3. A use according to claim 1 wherein the maximum dose is 800mg.

4. A use according to claim 1 wherein the series of dose increments consists of 2mg, 5mg, 12.5mg, 25mg, 50mg, 100mg, 200mg, 400mg and 800mg.

5. A use according to claim 1 wherein the peanut protein is administered as peanut flour.

6. A use according to claim 5 wherein the peanut flour is admixed with a carrier for administration.

7. A use according to claim 6 wherein the carrier is a dairy or dairy substitute product.

8. A use according to claim 1 comprising monitoring levels of serum anti-peanut IgE during the treatment.

9. A use according to claim 8 wherein the level of serum anti-peanut IgE in the serum of the individual is reduced or abolished by the treatment.

10. A set of therapeutic compositions, the set comprising multiple individual unit dose formulations comprising peanut protein,

wherein the amount of peanut protein in each unit dosage formulation in the set is identical and is selected from 2mg, 5mg, 12.5mg, 25mg, 50mg, 100mg, 200mg, 400mg and 800mg.

11. A group of sets of therapeutic compositions,

wherein each set in the group comprises multiple separate unit dose formulations comprising peanut protein and each unit dosage formulation in the set comprises an identical amount of peanut protein, and

wherein the group includes sets with unit dosage formulations which contain 2mg, 5mg, 12.5mg, 25mg, 50mg, 100mg, 200mg, 400mg and 800mg of peanut protein.

12. A set according to claim 10 wherein the set comprises fourteen unit dose formulations.

13. A set according to claim 10 wherein the unit dose formulations are separately packaged.

14. A set according to claim 10wherein the peanut protein is contained in peanut flour.

15. A set according to claim 14 wherein the peanut flour is admixed with a carrier for administration.

16. A set according to claim 15 wherein the carrier is a dairy or dairy substitute product.

17. A group of sets according to claim 11 wherein each set in the group comprises fourteen unit dose formulations.

18. A group of sets according to claim 11 wherein the unit dose formulations are separately packaged.

19. A group of sets according to claim 11 wherein each set in the group is separately packaged.

20. A group of sets according to claim 11 wherein the peanut protein is contained in peanut flour.

21. A group of sets according to claim 20 wherein the peanut flour is admixed with a carrier for administration.

Claims:

1. Use of peanut protein in the manufacture of a medicament fort the treatment of peanut allergy in an individual, wherein the medicament is to be administered as follows:

(1) wherein the medicament is to be orally administered daily, wherein the daily oral dose is increased at intervals of at least 2 weeks in a series of increments from an initial dose to a maximum dose, the series of dose increments including 2mg, 5mg, 12.5mg, 25mg, 50mg, 100mg, 200mg, 400mg and 800mg,

(2) wherein a daily oral dose of the maximum dose of peanut protein is to be administered for at least 2 years following step 1,

(3) wherein a weekly oral dose of the maximum dose of peanut protein is to be administered for at least 2 years following step 2.

2. A use according to claim 1 wherein the initial dose is 2mg

3. A use according to claim 1 wherein the maximum dose is 800mg.

4. A use according to claim 1 wherein the series of dose increments consists of 2mg, 5mg, 12.5mg, 25mg, 50mg, 100mg, 200mg, 400mg and 800mg.

5 A use according to claim 1 wherein the peanut protein is administered as peanut flour.

6. A use according to claim 5 wherein the peanut flour is admixed with a carrier for administration.

7. A use according to claim 6 wherein the carrier is a dairy or dairy substitute product.

8. A set of therapeutic compositions, the set comprising multiple individual unit dose formulations comprising peanut protein,

wherein the amount of peanut protein in each unit dosage formulation in the set is identical and is selected from 2mg, 5mg, 12.5mg, 25mg, 50mg, 100mg, 200mg, 400mg and 800mg.

9. A group of sets of therapeutic compositions,

wherein each set in the group comprises multiple separate unit dose formulations comprising peanut protein and each unit dosage formulation in the set comprises an identical amount of peanut protein, and

wherein the group includes sets with unit dosage formulations which contain 2mg, 5mg, 12.5mg, 25mg, 50mg, 100mg, 200mg, 400mg and 800mg of peanut protein.

10. A set according to claim 9 wherein the set comprises fourteen unit dose formulations.

11. A set according to claim 9 wherein the unit dose formulations are separately packaged. .

12. A set according to claim 9 wherein the peanut protein is contained in peanut flour

13. A set according to claim 12 wherein the peanut flour is admixed with a carrier for administration.

14. A set according to claim 13 wherein the carrier is a dairy or dairy substitute product.

15. A group of sets according to claim 9 wherein each set in the group comprises fourteen unit dose formulations.

16. A group of sets according to claim 9 wherein the unit dose formulations are separately packaged.

17. A group of sets according to claim 9 wherein each set in the group is separately packaged.

18. A group of sets according to claim 9wherein the peanut protein is contained in peanut flour

19. A group of sets according to claim 18 wherein the peanut flour is admixed with a carrier for administration.